Core Insights - InterDigital, Inc. has recognized Samir Ferdi as Inventor of the Year for his significant contributions to global wireless standards and innovation in secure, intelligent connectivity [1][2]. Company Overview - InterDigital is a global research and development company focused on wireless, video, artificial intelligence, and related technologies, providing foundational technologies for connected experiences across various products and services [6]. Innovation and Contributions - Samir Ferdi has been with InterDigital since 2007, playing a crucial role in the advancement of 4G and 5G technologies, including vehicle-to-everything (V2X) communications and cellular network security [3][4]. - His work has enabled practical applications in smartphones, IoT devices, and connected automobiles, showcasing the impact of his innovations across multiple industry verticals [3]. Leadership and Vision - InterDigital's CEO, Liren Chen, highlighted Samir's ability to identify challenges and develop forward-looking solutions that have strengthened the company's leadership in wireless research [4]. - The company's CTO, Rajesh Pankaj, emphasized that Samir's leadership in security and standards engagement exemplifies InterDigital's mission to invent technologies that empower a connected world [6].

Company Overview - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor aimed at treating cardiovascular risk and retinal diseases [3] - BioAge is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs that leverage insights from human longevity data [3] Upcoming Events - BioAge will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [1] - CEO Kristen Fortney and CFO Dov Goldstein will participate in a fireside chat and one-on-one meetings during the conference [2] - A live webcast of the presentation will be available, with replays accessible on the company's investor website for 30 days post-event [2] Clinical Development - A Phase 1 SAD/MAD trial of BGE-102 is currently underway, with topline data, including additional MAD cohorts, expected in the first half of 2026 [3]

Core Viewpoint - Host Hotels & Resorts, Inc. has updated its investor presentation for the fourth quarter of 2025, highlighting its position as the largest lodging real estate investment trust in the United States [1]. Company Overview - Host Hotels & Resorts, Inc. is an S&P 500 company and the largest lodging real estate investment trust, owning 71 properties in the United States and five properties internationally, totaling approximately 41,700 rooms [2]. - The company also holds non-controlling interests in seven domestic joint ventures, further expanding its footprint in the hospitality sector [2].

Core Viewpoint - SNDL Inc. is set to release its fourth quarter and full year 2025 financial results on March 12, 2026, before market opening [1] Company Overview - SNDL Inc. is one of the largest vertically integrated cannabis companies in Canada and the largest private-sector liquor and cannabis retailer [2] - The company operates retail banners including Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf [2] - SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future, and Bhang Chocolate [2] - The company aims to deploy strategic capital through direct and indirect investments and partnerships in the North American cannabis industry [2]

Core Insights - Bicara Therapeutics presented preliminary data from a Phase 1b expansion cohort evaluating ficerafusp alfa in combination with pembrolizumab for treating first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), showing rapid, deep, and durable responses with a well-tolerated safety profile [1][3][4] Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with ficerafusp alfa being its lead program [12][13] - Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration and improve survival outcomes by combining an EGFR-directed antibody with a TGF-β ligand trap [2][10] Clinical Data - The Phase 1b expansion cohort data indicated a 48% confirmed overall response rate (ORR) for the 2000mg every other week (Q2W) dosing regimen, with 26% of patients achieving a complete response (CR) and 77% of responders showing at least 80% tumor shrinkage [3][4] - The safety profile of the 2000mg Q2W regimen was consistent with previous findings for ficerafusp alfa combined with pembrolizumab [3][4] - Updated biomarker results confirmed that the 2000mg Q2W regimen maintains TGF-β inhibition and immune activation while delivering deep responses [5] Future Development Plans - The company plans to develop a loading and every-three-week maintenance regimen for ficerafusp alfa, pending regulatory alignment [1][6] - Ongoing enrollment in the pivotal FORTIFI-HN01 study continues to evaluate ficerafusp alfa at 1500mg weekly in combination with pembrolizumab [6][11] Industry Context - HNSCC is one of the most common cancers globally, with a rising incidence expected to reach one million new cases annually by 2030, highlighting a significant unmet need for effective therapies [8][9]

Core Viewpoint - U.S. Global Investors, Inc. will host a webcast on February 23, 2026, to discuss its second-quarter results for fiscal year 2026, with financial data to be released beforehand [1]. Group 1: Company Overview - U.S. Global Investors, Inc. has a history of over 50 years, starting as an investment club and evolving into a registered investment adviser focusing on niche markets globally [3]. - The company is headquartered in San Antonio, Texas, and provides investment management and services to U.S. Global Investors Funds and U.S. Global ETFs [3]. Group 2: Webcast Details - The webcast is scheduled for 7:30 a.m. Central time on February 23, 2026, featuring CEO Frank Holmes, CFO Lisa Callicotte, and Director of Marketing Holly Schoenfeldt [1]. - Registration for the webcast is available through a provided link [2].

Core Viewpoint - Olema Pharmaceuticals, Inc. is focused on developing targeted therapies for breast cancer and will present at the TD Cowen 46 Annual Health Care Conference on March 3, 2026 [1] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving outcomes for breast cancer patients and is advancing a pipeline of novel therapies [3] - The lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent KAT6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]

TLA’AMIN TERRITORY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (“Western”) and Qwoqwnes Forestry Holdings Limited Partnership, an entity beneficially owned and controlled by Tla’amin Nation (“Qwoqwnes”), have reached an agreement for the purchase by Qwoqwnes of a 100% ownership interest in the assets comprising Western’s Stillwater Forest Operation, located near Powell River, British Columbia (“BC”), for an aggregate purchase price of $80.0 million (the “Transaction”). The Sti ...

Core Insights - Westwood Holdings Group has announced that its Westwood Enhanced Income Series™ ETFs have surpassed $250 million in assets under management (AUM), with the Westwood Salient Enhanced Midstream Income ETF (MDST) specifically reaching $200 million in AUM [1][2][3] Group 1: Company Overview - Westwood Holdings Group is a boutique asset management firm that offers a diverse range of actively and passively-managed investment strategies, focusing on client-first approaches and long-term relationships [6][7] - The firm has over 40 years of experience in providing bespoke investment strategies and exceptional client service, adapting to changing markets with innovative solutions [6][7] Group 2: Product Offerings - The Enhanced Income Series™ includes multiple ETFs aimed at providing income and capital appreciation, with a focus on energy sector investments [3] - The Westwood Enhanced Income Opportunity ETF (YLDW) and the Westwood Salient Enhanced Energy Income ETF (WEEI) are part of this series, designed to generate high distributable monthly income through dividend yields and options premiums [3]

Core Viewpoint - Gran Tierra Energy Inc. has entered into a purchase and sale agreement to sell its remaining working interest in the Simonette asset for a total cash consideration of C$62.5 million, effective January 1, 2026, marking the company's exit from Simonette and focusing on financial strengthening through deleveraging and capital reallocation [1] Financial Transaction - The sale of the Simonette asset will generate cash proceeds of C$62.5 million, which will be used to deleverage the company's balance sheet [1] - The transaction is expected to close in the first quarter of 2026, pending customary closing conditions [1] Strategic Focus - The divestiture aligns with Gran Tierra's strategy of portfolio optimization, emphasizing free cash flow, disciplined capital allocation, and reallocating capital towards higher-return opportunities in core operating areas [1]